---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001305"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:22:03.819280+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma restates Q3 2023 financials; non-cash errors increase loss by $22.7M, expects going concern doubt

## Summary
- Audit Committee concludes Sep 30, 2023 financials unreliable due to valuation errors in contingent consideration, convertible notes, stock comp, and derivatives.
- Non-cash corrections: Predecessor period loss increased ~$22.7M; Successor period income increased ~$6.4M; contingent consideration liability up ~$6.7M.
- Company expects additional material weaknesses and will continue reporting substantial doubt about ability to continue as going concern for 12 months.
- Merger-related reclassification errors between APIC and accumulated deficit; further revisions possible.

## SEC filing metadata
- accession: 0001558370-24-001305
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000155837024001305/0001558370-24-001305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000155837024001305/aeon-20240214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001305
- JSON: https://secwatch.observer/filing/0001558370-24-001305.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001305.txt

## Key facts
- Auditor Changes
  AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: KPMG LLP
  source text: concluded that the Company’s previously issued financial statements as of and for the three and nine months ended September 30, 2023, included in the Company’s Quarterly Report on Form 10-Q filed on November 13, 2023 (the “Form 10-Q”) and its Registration Statement on Form S-1 (File No. 333-274094) filed on November 24, 2023 (as amended, the “Registration Statement”), should no longer be relied upon
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000155837024001305/0001558370-24-001305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.